881 COMBINATION THERAPY WITH EGFR1–2/VEGFR INHIBITOR (XL647) AND SORAFENIB IMPROVES OUTCOMES IN A PRE-CLINICAL MODEL OF HCC

Beatriz Mínguez; S. Toffanin; Anja Lachenmayer; Laia Cabellos; A. Villanueva; Analisa DiFeo; Pedro Melgar‐Lesmes; S N Thung; Scott L. Friedman; Josep M. Llovet

doi:10.1016/s0168-8278(10)60882-3

Related publications

Article2001

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix

Journal of Hepatology

Letter2018

Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC

Josep M. Llovet, Richard S. Finn

The Lancet Oncology

Article2016

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel,

Article2007

3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma

Josep M. Llovet, Vincenzo Mazzaferro, Serena Ricci, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Minghua Shan, M. Moscovici, D. Voliotis

European Journal of Cancer Supplements

Article2009

814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

María Reig, Jordi Rimola, Alejandro Forner, Carlos Rodríguez de Lope, Josep M. Llovet, Carmen Ayuso, Jordi Bruix